Skip to main content

Table 2 New drug prescribing on patient level.

From: Is new drug prescribing in primary care specialist induced?

Salmeterol/fluticasone    
  New drug N (%) Reference drug N (%) Relative Rate (95% CI)
   Medical specialist 103 (60.2%) 302 (16.9%) 3.56 (3.03–4.17)
   GP 68 (39.8%) 1,481 (83.1%) Ref.
Rofecoxib    
   Medical specialist 137 (23.0%) 1,445 (13.0%) 1.77 (1.51–2.06)
   GP 459 (77.0%) 9,656 (87.0%) Ref.
Esomeprazole    
   Medical specialist 53 (34.9%) 424 (19.6%) 1.78 (1.41–2.25)
   GP 99 (65.1%) 1,741 (80.4%) Ref.
Tiotropium    
   Medical specialist 293 (52.7%) 123 (14.5%) 3.64 (3.03–4.36)
   GP 263 (47.3%) 726 (85.5%) Ref.
Rosuvastatin    
   Medical specialist 89 (42.0%) 355 (39.5%) 1.06 (0.89–1.27)
   GP 123 (58.0%) 544 (60.5%) Ref.
Overall    
   Medical specialist 675 (40.0%) 2,649 (15.8%) 2.53 (2.37–2.71)
   GP 1,012 (60.0%) 14,148 (84.2%) Ref.
  1. Number of patients receiving their first prescription for a new or a reference drug from a medical specialist or GP six months after market introduction.